We appreciate Philips and colleagues’ interest in our report on the associations between liver injury markers and coronavirus 2019 (COVID‐19) mortality.((1)) They raised the question regarding the application of liver injury markers. However, several of their interpretations of our results are misleading or incorrect. We understand that use of aspartate aminotransferase (AST) in isolation cannot comprehensively characterize liver injury.